Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

56.64USD
23 Jun 2017
Change (% chg)

$-0.69 (-1.20%)
Prev Close
$57.33
Open
$57.27
Day's High
$57.36
Day's Low
$56.24
Volume
5,743,737
Avg. Vol
2,746,633
52-wk High
$77.10
52-wk Low
$46.01

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $93,310.69
Shares Outstanding(Mil.): 1,647.43
Dividend: 0.39
Yield (%): 2.75

Financials

  BMY.N Industry Sector
P/E (TTM): 19.64 14.09 19.01
EPS (TTM): 2.88 -- --
ROI: 19.92 -6.73 -5.03
ROE: 33.58 -6.18 -4.28

U.S. Supreme Court ruling threatens massive talc litigation against J&J

June 21 Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

Jun 21 2017

BRIEF-Bristol-Myers Squibb announces expiration of cash tender offer

* Bristol-Myers Squibb announces the expiration of its cash tender offer

Jun 21 2017

RPT-U.S. Supreme Court ruling threatens massive talc litigation against J&J

June 20 Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

Jun 21 2017

U.S. Supreme Court ruling threatens massive talc litigation against J&J

Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

Jun 20 2017

CORRECTED-U.S. Supreme Court ruling threatens massive talc litigation against J&J

June 20 Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

Jun 20 2017

Seattle Genetics halts late-stage study of leukemia drug

Seattle Genetics Inc said it would halt a late-stage study of its drug to treat a type of leukemia in older patients following a "higher rate" of deaths in patients on the drug compared with those on a placebo.

Jun 19 2017

UPDATE 3-Seattle Genetics halts late-stage study of leukemia drug

* Shares fall as much as 11 pct (Adds company's and analyst's comments; updates shares)

Jun 19 2017

BRIEF-Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co

* Bristol-Myers Squibb to sell manufacturing facility in swords, Ireland to SK Biotek Co., Ltd.

Jun 16 2017

BRIEF-Seattle Genetics, Bristol-Myers Squibb highlight interim phase 1/2 data

* Seattle Genetics and Bristol-Myers Squibb highlight interim phase 1/2 data evaluating combination of adcetris® (brentuximab vedotin) and opdivo® (nivolumab) in relapsed hodgkin lymphoma at the international conference on malignant lymphoma

Jun 15 2017

BRIEF-Bristol-Myers Squibb announces cash tender offer

* Announces cash tender offer for any and all of certain of its outstanding debt securities

Jun 14 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $136.43 +0.38
Pfizer Inc. (PFE.N) $34.17 +0.11
Merck & Co., Inc. (MRK.N) $66.16 +0.14
Sanofi SA (SASY.PA) €87.87 --
AstraZeneca plc (AZN.L) 5,401.00 -107.00
GlaxoSmithKline plc (GSK.L) 1,708.50 -13.50
Eli Lilly and Co (LLY.N) $83.89 -0.42
Roche Holding Ltd. (ROG.S) CHF252.80 0.00
Roche Holding Ltd. (RO.S) CHF254.25 -1.75

Earnings vs. Estimates